Navigation Links
FDA Accepts NDA Filing for Retigabine
Date:12/30/2009

ALISO VIEJO, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for the investigational drug retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA was successfully validated thus enabling the MAA review to commence. The filings were submitted on October 30, 2009.

About Retigabine

Retigabine is a neuronal potassium channel opener currently in late-stage development as an adjunctive treatment for adult patients with partial-onset seizures. In Phase III epilepsy trials, retigabine reduced seizure rates compared to patients taking placebo. The most common adverse reactions (incidence greater than or equal to 5% and twice placebo) across all completed trials to date are dizziness, fatigue, confusional state, vertigo, tremor, coordination abnormal, diplopia (double vision), disturbance in attention, asthenia (weakness), and visual blurring.

Retigabine Important Note

As an investigational drug, retigabine has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the treatment of any disease or illness. It may not be commercialized in the United States unless and until the FDA has approved a NDA. Similar restrictions apply in other countries.

Collaboration Agreement with GlaxoSmithKline

Valeant has a worldwide License and Collaboration Agreement with GlaxoSmithKline (NYSE: GSK), to develop and commercialize retigabine. Valeant will collaborate with GSK on the development and marketing of retigabine in the United States, Australia, New Zealand, Canada and Puerto Rico (Collaboration Territory) and GSK has an exclusive license to develop and commercialize retigabine in countries outside of the Collaboration Territory and certain backup compounds to retigabine worldwide.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)



    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com


SOURCE Valeant Pharmaceuticals International


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Center to Advance Palliative Care Director and MacArthur Recipient, Diane E. Meier, MD, Accepts Fellowship Post With Senate HELP Committee
2. Freudenberg-NOK CEO Accepts New Position
3. AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve
4. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
5. FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis
6. Erik Estrada Accepts Honorary Appointment from Project Lifesaver International
7. House Energy & Commerce Committee Accepts Independence at Home Pilot Program as Amendment During Health Bill Markup
8. FDA Accepts Tris Pharmas ANDA with Paragraph IV Certification for a Generic Equivalent to Delsym
9. Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
10. Specialty Hospitals of America Accepts First Patients in New Long Term Critical Care Hospital Located in South East Washington
11. FDA Accepts Final Section of NDA Filing for LUCASSIN(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... A new and improved Orgasm-Shot ... look and feel about themselves and their sexual encounters. A unique medical practice ... leakage head on with a ground breaking medical technique aimed to give women ...
(Date:6/26/2017)... ... 2017 , ... KICKICO , a protocol built on Ethereum for more ... catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will launch ... raising of funds through the power of many - has been around for about ...
(Date:6/25/2017)... ... ... lyric music video in Final Cut Pro X with ProLyric from Pixel Film Studios. Users ... to any song. ProLyric flies in the text for each section and it hovers around ... for optimal control. ProLyric makes editing any music video or text-based production easier than ever. ...
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the ... New Orleans. This is a new, greatly improved version of the Doctor Referral teaming ... requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... testing for medications in select Florida and Texas doctors' offices and clinics. This ... new application of genetic testing recognizes the role genes play in determining an ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... Inc., a biotechnology company focused on the development of novel ... and Head of Virology Kristin Bedard has been invited to ... Beyond meeting sponsored by Life Science Washington.  This Symposium ... PDT at the Agora Conference Center in Seattle, ... joined by other leaders in infectious disease research and the ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is ... for excellence as a Podiatrist in Alabama . ... at Family First Foot Care. He brings over 20 years of ... pain management and healthcare, to his role. ... Foot Care, PC is pleased to welcome you to ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 /PRNewswire/ ... diabetes. In a further effort to help spread lessons ... this condition, the International Diabetes Federation (IDF) and Eli ... come together for the second phase of the Bringing ... (BRIDGES 2), reaffirming their commitment to helping people with ...
Breaking Medicine Technology: